AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life
Acne-like skin rash is a common side effect from colorectal cancer treatment, often causing patients to postpone their treatments
LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself
Over two-thirds of...
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitorsÂ
Drug works similarly to other DNA...
AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1...
AACR: Researchers share promising results from MD Anderson clinical trials
ABSTRACTS: CT012, CT132, CT265Â Â
Researchers from Â鶹ӳ» MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings include a personalized vaccine combination therapy for colorectal cancer, the use of radiotherapy to avoid the toxicities of systemic treatments for kidney...
AACR: MD Anderson researchers share cancer breakthroughs
ABSTRACTS: 1186, 3746, 3763, 3776, 3824, 6367, 6384, 6396, 6424, 6427, 6436, 6438,
CHICAGO ― Researchers from Â鶹ӳ»...
AACR: MD Anderson’s John Weinstein elected Fellow of the AACR Academy
CHICAGO ― John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology...